Clinical Trials Sponsored by Verona Pharma Inc

Total 2525 results

Astellas Pharma Global Development, Inc.

Recruiting

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease

Intraoperative Ureter Visualization | Abdominolpelvic Surgery

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Chronic Kidney Disease | Renal Anemia

Romania, Spain, Belgium, Germany, Norway, Slovakia, Denmark
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery

Intraoperative Ureter Visualization | Abdominolpelvic Surgery

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Japan, Korea, Republic of
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma (ILUSTRO)

Gastric Cancer | Pharmacokinetics of Zolbetuximab | Gastro-esophageal Junction (GEJ) Cancer | Pharmacokinetics of Oxaliplatin | Pharmacokinetics of Fluorouracil Bolus (5-FU)

United States, Japan, Italy, Korea, Republic of, Taiwan, France
Astellas Pharma Global Development, Inc.

Available

Early Access Program for Zolbetuximab

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma Cancer

United States, Germany
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States, Korea, Republic of, Japan, China, France, Turkey, Italy, Australia, Brazil, Ireland, Mexico, Spain, Taiwan
Astellas Pharma Global Development, Inc.

Completed

A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well

Renal Impairment | Healthy Volunteers

United States, Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

Renal Impairment | Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause (Skylight 4)

Hot Flashes

United States, Czechia, Canada, Latvia, Poland, Spain, Ukraine, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)

Hot Flashes | Menopause

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2 (Skylight 2)

Hot Flashes

United States, Canada, Czechia, United Kingdom, Latvia, Poland, Spain
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)

Cytomegalovirus (CMV)-Positive Recipients | Allogeneic, Hematopoietic Cell Transplant (HCT)

Japan, Korea, Republic of, United States, Canada, Australia, Belgium, France, Germany, Spain, Sweden, Taiwan
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States
Astellas Pharma Global Development, Inc.

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Schizophrenia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Canada
Astellas Pharma Global Development, Inc.

Approved for marketing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

United States, Canada, Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

Fibromyalgia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

Healthy Subjects

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

Relapsed Lymphoid Malignancy | Refractory Lymphoid Malignancy

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) (PREFER)

Overactive Bladder (OAB)

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor Mutations

United States
Astellas Pharma Global Development, Inc.

Completed

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer (PILOT)

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric Adenocarcinoma

Germany, Latvia
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Assess ASP2713 in Healthy Subjects

Healthy Volunteers
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis (RA)

United States, Poland
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

Lymphoma | Advanced Cancer | Refractory Solid Tumors

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Moldova, Republic of
Astellas Pharma Global Development, Inc.

Completed

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

Advanced Solid Tumors | Pharmacokinetics of 14C-OSI-906

United States
Astellas Pharma Inc
Astellas Pharma Global Development, Inc.

Completed

An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Solid Tumors

United States, Japan, Korea, Republic of, Taiwan
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) Mutations

United States
Astellas Pharma Global Development, Inc.

Completed

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

Healthy Volunteers | Pharmacokinetics of ASP1941

United States
Viron Therapeutics Inc

Terminated

Serp-1 for the Treatment of Acute Coronary Syndrome

Unstable Angina | Coronary Atherosclerosis | Coronary Restenosis

United States, Canada
Astellas Pharma Inc

Recruiting

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Solid Tumor

United States
InnoCare Pharma Inc.

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies

Mature B-cell Malignancies
Telios Pharma, Inc.

Recruiting

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Dry Eye Disease

United States
Astellas Pharma Inc

Recruiting

A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause (Starlight 3)

Hot Flashes

Japan
SpyGlass Pharma, Inc.

Recruiting

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution (Tigris)

Ocular Hypertension | Glaucoma | Cataract

United States
Vincerx Pharma, Inc.

Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Acute Myeloid Leukemia | B-cell Acute Lymphoblastic Leukemia | High-risk Myelodysplastic Syndrome

United States
Lantern Pharma Inc.

Recruiting

Study of LP-184 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
CinDome Pharma, Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Diabetic Gastroparesis

United States
Lavior Pharma Inc.

Recruiting

Restoring Tissue and Evaluating Novel Treatments for Efficacy in Wounds (RENEW)

Diabetic Foot Ulcer

United States
Sinew Pharma Inc.

Recruiting

A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers

Hepatitis | Pharmacology

Taiwan

Clinical Trials Sponsored by Verona Pharma Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations